胃がん(Gastric Cancer):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Gastric Cancer - Pipeline Review, H2 2014
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC5678IDB
◆発行日:2014年11月18日
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:610
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[胃がん(Gastric Cancer):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら
当調査レポートでは、世界における胃がん(Gastric Cancer)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・胃がん(Gastric Cancer)の概要
・胃がん(Gastric Cancer)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・胃がん(Gastric Cancer)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・胃がん(Gastric Cancer)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・胃がん(Gastric Cancer)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
*** レポート概要(サマリー)***

Gastric Cancer – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Gastric Cancer – Pipeline Review, H2 2014’, provides an overview of the Gastric Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastric Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Gastric Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Gastric Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastric Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastric Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastric Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
Introduction 7
Gastric Cancer Overview 8
Therapeutics Development 9
Gastric Cancer – Therapeutics under Development by Companies 11
Gastric Cancer – Therapeutics under Investigation by Universities/Institutes 20
Gastric Cancer – Pipeline Products Glance 22
Gastric Cancer – Products under Development by Companies 26
Gastric Cancer – Products under Investigation by Universities/Institutes 38
Gastric Cancer – Companies Involved in Therapeutics Development 39
Gastric Cancer – Therapeutics Assessment 141
Drug Profiles 161
Gastric Cancer – Recent Pipeline Updates 445
Gastric Cancer – Dormant Projects 573
Gastric Cancer – Discontinued Products 580
Gastric Cancer – Product Development Milestones 582
Appendix 590

[List of Tables]
Number of Products under Development for Gastric Cancer, H2 2014 28
Number of Products under Development for Gastric Cancer - Comparative Analysis, H2 2014 29
Number of Products under Development by Companies, H2 2014 31
Number of Products under Development by Companies, H2 2014 (Contd..1) 32
Number of Products under Development by Companies, H2 2014 (Contd..2) 33
Number of Products under Development by Companies, H2 2014 (Contd..3) 34
Number of Products under Development by Companies, H2 2014 (Contd..4) 35
Number of Products under Development by Companies, H2 2014 (Contd..5) 36
Number of Products under Development by Companies, H2 2014 (Contd..6) 37
Number of Products under Development by Companies, H2 2014 (Contd..7) 38
Number of Products under Investigation by Universities/Institutes, H2 2014 40
Comparative Analysis by Late Stage Development, H2 2014 41
Comparative Analysis by Clinical Stage Development, H2 2014 42
Comparative Analysis by Early Stage Development, H2 2014 43
Comparative Analysis by Unknown Stage Development, H2 2014 44
Products under Development by Companies, H2 2014 45
Products under Development by Companies, H2 2014 (Contd..1) 46
Products under Development by Companies, H2 2014 (Contd..2) 47
Products under Development by Companies, H2 2014 (Contd..3) 48
Products under Development by Companies, H2 2014 (Contd..4) 49
Products under Development by Companies, H2 2014 (Contd..5) 50
Products under Development by Companies, H2 2014 (Contd..6) 51
Products under Development by Companies, H2 2014 (Contd..7) 52
Products under Development by Companies, H2 2014 (Contd..8) 53
Products under Development by Companies, H2 2014 (Contd..9) 54
Products under Development by Companies, H2 2014 (Contd..10) 55
Products under Development by Companies, H2 2014 (Contd..11) 56
Products under Investigation by Universities/Institutes, H2 2014 57
Gastric Cancer - Pipeline by AB Science, H2 2014 58
Gastric Cancer - Pipeline by AbbVie Inc., H2 2014 59
Gastric Cancer - Pipeline by AbGenomics International, Inc., H2 2014 60
Gastric Cancer - Pipeline by Advaxis, Inc., H2 2014 61
Gastric Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2014 62
Gastric Cancer - Pipeline by AlphaMab Co., Ltd, H2 2014 63
Gastric Cancer - Pipeline by Ambrx, Inc., H2 2014 64
Gastric Cancer - Pipeline by Amgen Inc., H2 2014 65
Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2014 66
Gastric Cancer - Pipeline by Astellas Pharma Inc., H2 2014 67
Gastric Cancer - Pipeline by AstraZeneca PLC, H2 2014 68
Gastric Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2014 69
Gastric Cancer - Pipeline by Avipep Pty Ltd, H2 2014 70
Gastric Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2014 71
Gastric Cancer - Pipeline by Basilea Pharmaceutica AG, H2 2014 72
Gastric Cancer - Pipeline by Bayer AG, H2 2014 73
Gastric Cancer - Pipeline by BioMarin Pharmaceutical Inc., H2 2014 74
Gastric Cancer - Pipeline by Biotecnol, Inc., H2 2014 75
Gastric Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 76
Gastric Cancer - Pipeline by Boston Biomedical, Inc., H2 2014 77
Gastric Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 78
Gastric Cancer - Pipeline by Celgene Corporation, H2 2014 79
Gastric Cancer - Pipeline by Celltrion, Inc., H2 2014 80
Gastric Cancer - Pipeline by Celon Pharma Sp. z o.o., H2 2014 81
Gastric Cancer - Pipeline by Cerulean Pharma, Inc., H2 2014 82
Gastric Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2014 83
Gastric Cancer - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014 84
Gastric Cancer - Pipeline by Covagen AG, H2 2014 85
Gastric Cancer - Pipeline by DAE HWA Pharmaceutical Co., Ltd., H2 2014 86
Gastric Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 87
Gastric Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2014 88
Gastric Cancer - Pipeline by DiaMedica Inc., H2 2014 89
Gastric Cancer - Pipeline by Dong-A Socio Group, H2 2014 90
Gastric Cancer - Pipeline by Eddingpharm, H2 2014 91
Gastric Cancer - Pipeline by Eli Lilly and Company, H2 2014 92
Gastric Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 93
Gastric Cancer - Pipeline by Erytech Pharma SA, H2 2014 94
Gastric Cancer - Pipeline by F-star Alpha Ltd., H2 2014 95
Gastric Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 96
Gastric Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2014 97
Gastric Cancer - Pipeline by Galaxy Biotech, LLC, H2 2014 98
Gastric Cancer - Pipeline by Galena Biopharma, Inc., H2 2014 99
Gastric Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2014 100
Gastric Cancer - Pipeline by Genentech, Inc., H2 2014 101
Gastric Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 102
Gastric Cancer - Pipeline by GlycoNex Inc., H2 2014 103
Gastric Cancer - Pipeline by Glycotope GmbH, H2 2014 104
Gastric Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 105
Gastric Cancer - Pipeline by Hutchison MediPharma Limited, H2 2014 106
Gastric Cancer - Pipeline by ImmunoGen, Inc., H2 2014 107
Gastric Cancer - Pipeline by Immunomedics, Inc., H2 2014 108
Gastric Cancer - Pipeline by Imugene Limited, H2 2014 109
Gastric Cancer - Pipeline by Incuron, LLC, H2 2014 110
Gastric Cancer - Pipeline by INSYS Therapeutics, Inc., H2 2014 111
Gastric Cancer - Pipeline by Intezyne, Inc, H2 2014 112
Gastric Cancer - Pipeline by ISU ABXIS Co.,Ltd., H2 2014 113
Gastric Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2014 114
Gastric Cancer - Pipeline by Kadmon Corporation, LLC, H2 2014 115
Gastric Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 116
Gastric Cancer - Pipeline by Kinex Pharmaceuticals, LLC, H2 2014 117
Gastric Cancer - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2014 118
Gastric Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 119
Gastric Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2014 120
Gastric Cancer - Pipeline by MacroGenics, Inc., H2 2014 121
Gastric Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2014 122
Gastric Cancer - Pipeline by Merck & Co., Inc., H2 2014 123
Gastric Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 124
Gastric Cancer - Pipeline by Mersana Therapeutics, Inc., H2 2014 125
Gastric Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 126
Gastric Cancer - Pipeline by Molecular Targeting Technologies, Inc., H2 2014 127
Gastric Cancer - Pipeline by MSM Protein Technologies, Inc., H2 2014 128
Gastric Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2014 129
Gastric Cancer - Pipeline by NeoPharm Co., Ltd., H2 2014 130
Gastric Cancer - Pipeline by Neopharm Ltd., H2 2014 131
Gastric Cancer - Pipeline by New Medical Enzymes AG, H2 2014 132
Gastric Cancer - Pipeline by Novartis AG, H2 2014 133
Gastric Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2014 134
Gastric Cancer - Pipeline by OncoTherapy Science, Inc., H2 2014 135
Gastric Cancer - Pipeline by Oncothyreon Inc., H2 2014 136
Gastric Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 137
Gastric Cancer - Pipeline by Oxford BioTherapeutics Ltd, H2 2014 138
Gastric Cancer - Pipeline by Panacea Biotec Limited, H2 2014 139
Gastric Cancer - Pipeline by Patrys Limited, H2 2014 140
Gastric Cancer - Pipeline by Pfizer Inc., H2 2014 141
Gastric Cancer - Pipeline by Pharmacyclics, Inc., H2 2014 142
Gastric Cancer - Pipeline by Priaxon AG, H2 2014 143
Gastric Cancer - Pipeline by Recepta Biopharma S.A., H2 2014 144
Gastric Cancer - Pipeline by Regulon Inc., H2 2014 145
Gastric Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2014 146
Gastric Cancer - Pipeline by Richter Gedeon Nyrt., H2 2014 147
Gastric Cancer - Pipeline by Sanofi, H2 2014 148
Gastric Cancer - Pipeline by Sareum Holdings plc, H2 2014 149
Gastric Cancer - Pipeline by SentoClone International AB, H2 2014 150
Gastric Cancer - Pipeline by Sequella, Inc., H2 2014 151
Gastric Cancer - Pipeline by Siena Biotech S.p.A., H2 2014 152
Gastric Cancer - Pipeline by Supratek Pharma Inc., H2 2014 153
Gastric Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 154
Gastric Cancer - Pipeline by Synthon BV, H2 2014 155
Gastric Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2014 156
Gastric Cancer - Pipeline by Tesaro, Inc., H2 2014 157
Gastric Cancer - Pipeline by Vaxon Biotech, H2 2014 158
Gastric Cancer - Pipeline by Zymeworks Inc., H2 2014 159
Assessment by Monotherapy Products, H2 2014 160
Assessment by Combination Products, H2 2014 161
Number of Products by Stage and Target, H2 2014 163
Number of Products by Stage and Mechanism of Action, H2 2014 171
Number of Products by Stage and Route of Administration, H2 2014 177
Number of Products by Stage and Molecule Type, H2 2014 179
Gastric Cancer Therapeutics - Recent Pipeline Updates, H2 2014 464
Gastric Cancer - Dormant Projects, H2 2014 592
Gastric Cancer - Dormant Projects (Contd..1), H2 2014 593
Gastric Cancer - Dormant Projects (Contd..2), H2 2014 594
Gastric Cancer - Dormant Projects (Contd..3), H2 2014 595
Gastric Cancer - Dormant Projects (Contd..4), H2 2014 596
Gastric Cancer - Dormant Projects (Contd..5), H2 2014 597
Gastric Cancer - Dormant Projects (Contd..6), H2 2014 598
Gastric Cancer - Discontinued Products, H2 2014 599
Gastric Cancer - Discontinued Products (Contd..1), H2 2014 600



[List of Figures]
Number of Products under Development for Gastric Cancer, H2 2014 28
Number of Products under Development for Gastric Cancer - Comparative Analysis, H2 2014 29
Number of Products under Development by Companies, H2 2014 30
Number of Products under Investigation by Universities/Institutes, H2 2014 39
Comparative Analysis by Late Stage Development, H2 2014 41
Comparative Analysis by Clinical Stage Development, H2 2014 42
Comparative Analysis by Early Stage Products, H2 2014 43
Assessment by Monotherapy Products, H2 2014 160
Assessment by Combination Products, H2 2014 161
Number of Products by Top 10 Targets, H2 2014 162
Number of Products by Stage and Top 10 Targets, H2 2014 162
Number of Products by Top 10 Mechanism of Actions, H2 2014 170
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 170
Number of Products by Top 10 Routes of Administration, H2 2014 176
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 176
Number of Products by Top 10 Molecule Types, H2 2014 178
Number of Products by Stage and Top 10 Molecule Types, H2 2014 178

*** 掲載企業 ***

AB Science
AbbVie Inc.
AbGenomics International, Inc.
Advaxis, Inc.
Advenchen Laboratories, LLC
AlphaMab Co., Ltd
Ambrx, Inc.
Amgen Inc.
Aslan Pharmaceuticals Pte. Ltd.
Astellas Pharma Inc.
AstraZeneca PLC
AVEO Pharmaceuticals, Inc.
Avipep Pty Ltd
Azaya Therapeutics Incorporated
Basilea Pharmaceutica AG
Bayer AG
BioMarin Pharmaceutical Inc.
Biotecnol, Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Celltrion, Inc.
Celon Pharma Sp. z o.o.
Cerulean Pharma, Inc.
Chipscreen Biosciences Ltd
Chugai Pharmaceutical Co., Ltd.
Covagen AG
DAE HWA Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Deciphera Pharmaceuticals, LLC
DiaMedica Inc.
Dong-A Socio Group
Eddingpharm
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
Erytech Pharma SA
F-star Alpha Ltd.
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Galaxy Biotech, LLC
Galena Biopharma, Inc.
Ganymed Pharmaceuticals AG
Genentech, Inc.
GlaxoSmithKline plc
GlycoNex Inc.
Glycotope GmbH
Hanmi Pharmaceuticals, Co. Ltd.
Hutchison MediPharma Limited
ImmunoGen, Inc.
Immunomedics, Inc.
Imugene Limited
Incuron, LLC
INSYS Therapeutics, Inc.
Intezyne, Inc
ISU ABXIS Co.,Ltd.
Jiangsu Kanion Pharmaceutical Co., Ltd.
Kadmon Corporation, LLC
Karyopharm Therapeutics, Inc.
Kinex Pharmaceuticals, LLC
Kuhnil Pharmaceutical Co., Ltd.
Kyowa Hakko Kirin Co., Ltd.
Les Laboratoires Servier SAS
MacroGenics, Inc.
Mebiopharm Co., Ltd.
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
Mersana Therapeutics, Inc.
Millennium Pharmaceuticals, Inc.
Molecular Targeting Technologies, Inc.
MSM Protein Technologies, Inc.
NanoCarrier Co., Ltd.
NeoPharm Co., Ltd.
Neopharm Ltd.
New Medical Enzymes AG
Novartis AG
Omnitura Therapeutics Inc.
OncoTherapy Science, Inc.
Oncothyreon Inc.
Ono Pharmaceutical Co., Ltd.
Oxford BioTherapeutics Ltd
Panacea Biotec Limited
Patrys Limited
Pfizer Inc.
Pharmacyclics, Inc.
Priaxon AG
Recepta Biopharma S.A.
Regulon Inc.
Rexahn Pharmaceuticals, Inc.
Richter Gedeon Nyrt.
Sanofi
Sareum Holdings plc
SentoClone International AB
Sequella, Inc.
Siena Biotech S.p.A.
Supratek Pharma Inc.
Synta Pharmaceuticals Corp.
Synthon BV
Taiho Pharmaceutical Co., Ltd.
Tesaro, Inc.
Vaxon Biotech
Zymeworks Inc.

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC5678IDB )"胃がん(Gastric Cancer):治療薬開発パイプライン動向(2014年下半期版)" (英文:Gastric Cancer - Pipeline Review, H2 2014)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。